Amylin maintained by Merrill at sell

Amylin Pharmaceuticals was maintained by Merrill Lynch analyst Thomas McGahren at a sell rating pending further clarity on the FDA's clinical trial requirements for Exenatide LAR as the stock at current levels is pricing in generous estimates. The rating is also pending fourth-quarter results set to be released Feb. 9, Merrill said. New and total scripts of Byetta have been relatively flat over the last six to eight weeks and it is unclear how well they are tracking demand in view of sampling, stocking and mail orders, Merrill said. Shares of the San Diego pharmaceutical company were up 39 cents, or 0.90%, at $43.49 on volume of 2,936,498 shares versus the three-month running average of 2,205,890 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.